Attached files
| file | filename |
|---|---|
| EX-32.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INC | f10q1220ex32-1_pluristem.htm |
| EX-31.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INC | f10q1220ex31-2_pluristem.htm |
| EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INC | f10q1220ex31-1_pluristem.htm |
| EX-10.1 - FORM OF DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT - PLURISTEM THERAPEUTICS INC | f10q1220ex10-1_pluristem.htm |
| 10-Q - QUARTERLY REPORT - PLURISTEM THERAPEUTICS INC | f10q1220_pluristem.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
In connection with the Quarterly Report (the “Report”) of Pluristem Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof, I, Chen Franco-Yehuda, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, that to my knowledge:
| 1. | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: February 8, 2021 | By: | /s/ Chen Franco-Yehuda |
| Chen Franco-Yehuda | ||
| Chief Financial Officer | ||